Novel and functional ABCB1 gene variant in sporadic Parkinson's disease

Neuroscience Letters

Volumn 566, Issue , 2014, Pages 61-66

  Li, Yuequn ^a   Li, Yonghua ^a   Pang, Shuchao ^a   Huang, Wenhui ^a   Zhang, Aimei ^a   Hawley, Robert G ^a,b   Yan, Bo ^a,b  

^a JINING MEDICAL UNIVERSITY   (China)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

ABCB1; DNA sequence variants; Parkinson's disease; Promoter

Indexed keywords

DNA FRAGMENT; MULTIDRUG RESISTANCE PROTEIN 1; TOXIC SUBSTANCE;

AGED; ARTICLE; BLOOD BRAIN BARRIER; BRAIN TISSUE; BRAIN TOXICITY; COMPARATIVE STUDY; CONTROLLED STUDY; DNA SEQUENCE; ENVIRONMENTAL FACTOR; FEMALE; FUNCTIONAL GENOMICS; GENE ACTIVITY; GENE CONTROL; GENE DELETION; GENE EXPRESSION; GENETIC VARIABILITY; HEREDITY; HUMAN; INDEL MUTATION; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM;

ABCB1; DNA SEQUENCE VARIANTS; PARKINSON'S DISEASE; PROMOTER;

AGED; CASE-CONTROL STUDIES; FEMALE; GENETIC VARIATION; HEK293 CELLS; HUMANS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; PARKINSON DISEASE; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

EID: 84896098989     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2014.02.025     Document Type: Article

References (50)

1. Martin I., Dawson V.L., Dawson T.M. Recent advances in the genetics of Parkinson's disease. Annu. Rev. Genomics Hum. Genet. 2011, 12:301-325.
2. Shulman J.M., De Jager P.L., Feany M.B. Parkinson's disease: genetics and pathogenesis. Annu. Rev. Pathol. 2011, 6:193-222.
3. Singleton A.B., Farrer M.J., Bonifati V. The genetics of Parkinson's disease: progress and therapeutic implications. Mov. Disord. 2013, 28:14-23.
4. Binkhathlan Z., Lavasanifar A. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives. Curr. Cancer Drug Targets 2013, 13:326-346.
5. Hawley T.S., Riz I., Yang W., Wakabayashi Y., DePalma L., Chang Y.T., Peng W., Zhu J., Hawley R.G. Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1. Am. J. Hematol. 2013, 88:265-272.
6. Vautier S., Fernandez C. ABCB1: the role in Parkinson's disease and pharmacokinetics of antiparkinsonian drugs. Expert Opin. Drug Metab. Toxicol. 2009, 5:1349-1358.
7. Zhang C., Kwan P., Zuo Z., Baum L. The transport of antiepileptic drugs by P-glycoprotein. Adv. Drug Deliv. Rev. 2012, 64:930-942.
8. Cordon-Cardo C., O'Brien J.P., Boccia J., Casals D., Bertino J.R., Melamed M.R. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J. Histochem. Cytochem. 1990, 38:1277-1287.
9. Cordon-Cardo C., O'Brien J.P., Casals D., Rittman-Grauer L., Biedler J.L., Melamed M.R., Bertino J.R. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:695-698.
10. Fojo A.T., Ueda K., Slamon D.J., Poplack D.G., Gottesman M.M., Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc. Natl. Acad. Sci. U. S. A. 1987, 84:265-269.
11. Drach D., Zhao S., Drach J., Mahadevia R., Gattringer C., Huber H., Andreeff M. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 1992, 80:2729-2734.
12. Klimecki W.T., Futscher B.W., Grogan T.M., Dalton W.S. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 1994, 83:2451-2458.
13. Bartels A.L. Blood-brain barrier P-glycoprotein function in neurodegenerative disease. Curr. Pharm. Des. 2011, 17:2771-2777.
14. Dutheil F., Beaune P., Tzourio C., Loriot M.A., Elbaz A. Interaction between ABCB1 and professional exposure to organochlorine insecticides in Parkinson disease. Arch. Neurol. 2010, 67:739-745.
15. Lee C.G., Tang K., Cheung Y.B., Wong L.P., Tan C., Shen H., Zhao Y., Pavanni R., Lee E.J., Wong M.C., Chong S.S., Tan E.K. MDR1, the blood-brain barrier transporter, is associated with Parkinson's disease in ethnic Chinese. J. Med. Genet. 2004, 41:e60.
16. Tan E.K., Chan D.K., Ng P.W., Woo J., Teo Y.Y., Tang K., Wong L.P., Chong S.S., Tan C., Shen H., Zhao Y., Lee C.G. Effect of MDR1 haplotype on risk of Parkinson disease. Arch. Neurol. 2005, 62:460-464.
17. Westerlund M., Belin A.C., Anvret A., Håkansson A., Nissbrandt H., Lind C., Sydow O., Olson L., Galter D. Association of a polymorphism in the ABCB1 gene with Parkinsonås disease. Parkinsonism Relat. Disord. 2009, 15:422-424.
18. Zschiedrich K., König I.R., Brüggemann N., Kock N., Kasten M., Leenders K.L., Kostić V., Vieregge P., Ziegler A., Klein C., Lohmann K. MDR1 variants and risk of Parkinson disease. Association with pesticide exposure?. J. Neurol. 2009, 256:115-120.
19. Droździk M., Białecka M., Myśliwiec K., Honczarenko K., Stankiewicz J., Sych Z. Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinsonźs disease. Pharmacogenetics 2003, 13:259-263.
20. Funke C., Soehn A.S., Tomiuk J., Riess O., Berg D. Genetic analysis of coding SNPs in blood-brain barrier transporter MDR1 in European Parkinson's disease patients. J. Neural. Transm. 2009, 116:443-450.
21. Furuno T., Landi M.T., Ceroni M., Caporaso N., Bernucci I., Nappi G., Martignoni E., Schaeffeler E., Eichelbaum M., Schwab M., Zanger U.M. Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics 2002, 12:529-534.
22. Tan E.K., Drozdzik M., Bialecka M., Honczarenko K., Klodowska-Duda G., Teo Y.Y., Tang K., Wong L.P., Chong S.S., Tan C., Yew K., Zhao Y., Lee C.G. Analysis of MDR1 haplotypes in Parkinson's disease in a white population. Neurosci. Lett. 2004, 372:240-244.
23. Bartels A.L., Willemsen A.T., Kortekaas R., de Jong B.M., de Vries R., de Klerk O., van Oostrom J.C., Portman A., Leenders K.L. Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA. J. Neural. Transm. 2008, 115:1001-1009.
24. Kortekaas R., Leenders K.L., van Oostrom J.C., Vaalburg W., Bart J., Willemsen A.T., Hendrikse N.H. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann. Neurol. 2005, 57:176-179.
25. Westerlund M., Belin A.C., Olson L., Galter D. Expression of multi-drug resistance 1 mRNA in human and rodent tissues: reduced levels in Parkinson patients. Cell Tissue Res. 2008, 334:179-185.
26. Takane H., Kobayashi D., Hirota T., Kigawa J., Terakawa N., Otsubo K., Ieiri I. Haplotype-oriented genetic analysis and functional assessment of promoter variants in the MDR1 (ABCB1) gene. J. Pharmacol. Exp. Ther. 2004, 311:1179-1187.
27. Callen D.F., Baker E., Simmers R.N., Seshadri R., Roninson I.B. Localization of the human multiple drug resistance gene, MDR1, to 7q21.1. Hum. Genet. 1987, 77:142-144.
28. Chen C.J., Chin J.E., Ueda K., Clark D.P., Pastan I., Gottesman M.M., Roninson I.B. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986, 47:381-389.
29. Riordan J.R., Deuchars K., Kartner N., Alon N., Trent J., Ling V. Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature 1985, 316:817-819.
30. Ueda K., Cornwell M.M., Gottesman M.M., Pastan I., Roninson I.B., Ling V., Riordan J.R. The mdr1 gene, responsible for multidrug-resistance, codes for P-glycoprotein. Biochem. Biophys. Res. Commun. 1986, 141:956-962.
31. Kohno K., Sato S., Uchiumi T., Takano H., Kato S., Kuwano M. Tissue-specific enhancer of the human multidrug-resistance (MDR1) gene. J. Biol. Chem. 1990, 265:19690-19696.
32. Ueda K., Pastan I., Gottesman M.M. Isolation and sequence of the promoter region of the human multidrug-resistance (P-glycoprotein) gene. J. Biol. Chem. 1987, 262:17432-17436.
33. Wang B., Ngoi S., Wang J., Chong S.S., Lee C.G. The promoter region of the MDR1 gene is largely invariant, but different single nucleotide polymorphism haplotypes affect MDR1 promoter activity differently in different cell lines. Mol. Pharmacol. 2006, 70:267-276.
34. Comerford K.M., Wallace T.J., Karhausen J., Louis N.A., Montalto M.C., Colgan S.P. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 2002, 62:3387-3394.
35. Gromnicova R., Romero I., Male D. Transcriptional control of the multi-drug transporter ABCB1 by transcription factor Sp3 in different human tissues. PLoS One 2012, 7:e48189.
36. Han C.Y., Cho K.B., Choi H.S., Han H.K., Kang K.W. Role of FoxO1 activation in MDR1 expression in adriamycin-resistant breast cancer cells. Carcinogenesis 2008, 29:1837-1844.
37. Hui R.C., Francis R.E., Guest S.K., Costa J.R., Gomes A.R., Myatt S.S., Brosens J.J., Lam E.W. Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells. Mol. Cancer Ther. 2008, 7:670-678.
38. Jin S., Scotto K.W. Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y. Mol. Cell Biol. 1998, 18:4377-4384.
39. Labialle S., Gayet L., Marthinet E., Rigal D., Baggetto L.G. Transcriptional regulators of the human multidrug resistance 1 gene: recent views. Biochem. Pharmacol. 2002, 64:943-948.
40. Tao W., Shi J.F., Zhang Q., Xue B., Sun Y.J., Li C.J. Egr-1 enhances drug resistance of breast cancer by modulating MDR1 expression in a GGPPS-independent manner. Biomed. Pharmacother. 2013, 67:197-202.
41. Henrique R., Oliveira A.I., Costa V.L., Baptista T., Martins A.T., Morais A., Oliveira J., Jerónimo C. Epigenetic regulation of MDR1 gene through post-translational histone modifications in prostate cancer. BMC Genomics 2013, 14:898.
42. Krishnamurthy K., Vedam K., Kanagasabai R., Druhan L.J., Ilangovan G. Heat shock factor-1 knockout induces multidrug resistance gene, MDR1b, and enhances P-glycoprotein (ABCB1)-based drug extrusion in the heart. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:9023-9028.
43. Deleidi M., Gasser T. The role of inflammation in sporadic and familial Parkinson's disease. Cell Mol. Life Sci. 2013, 70:4259-4273.
44. Hirsch E.C., Jenner P., Przedborski S. Pathogenesis of Parkinson's disease. Mov. Disord. 2013, 28:24-30.
45. Erickson M.A., Dohi K., Banks W.A. Neuroinflammation: a common pathway in CNS diseases as mediated at the blood-brain barrier. Neuroimmunomodulation 2012, 19:121-130.
46. Fernandez C., Buyse M., German-Fattal M., Gimenez F. Influence of the pro-inflammatory cytokines on P-glycoprotein expression and functionality. J. Pharm. Pharm. Sci. 2004, 7:359-371.
47. Poller B., Drewe J., Krähenbühl S., Huwyler J., Gutmann H. Regulation of BCRP (ABCG2) and P-glycoprotein (ABCB1) by cytokines in a model of the human blood-brain barrier. Cell Mol. Neurobiol. 2010, 30:63-70.
48. Gibson C.J., Hossain M.M., Richardson J.R., Aleksunes L.M. Inflammatory regulation of ATP binding cassette efflux transporter expression and function in microglia. J. Pharmacol. Exp. Ther. 2012, 343:650-660.
49. Jangula A., Murphy E.J. Lipopolysaccharide-induced blood-brain barrier permeability is enhanced by alpha-synuclein expression. Neurosci. Lett. 2013, 551:23-27.
50. Rapposelli S., Digiacomo M., Balsamo A. P-gp transporter and its role in neurodegenerative diseases. Curr. Top. Med. Chem. 2009, 9:209-217.